ibrutinib,venetoclax,avelumab
pfizer,merck,janssen,roche,pharmacyclics,abbvie
['captivate trial', 'cll', 'venetoclax', ' ibru', 'captivate study', ' ave ', 'glow', 'lymsm']
congress | #ash22 john n. allan of presents a 5-year follow-up of the phase ii captivate trial of ibr +ven in patients with #cll. the results further support the use of this treatment protocol based on the favorable benefit-risk profile.
#lymsm #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm